NCT07508904Recruiting
Exercises' Effect on Muscle Strength, Aerobic Capacity and Respiratory Functions in Cystic Fibrosis
Effects of Upper and Lower Limb Exercises on Muscle Strength, Aerobic Capacity and Respiratory Functions in Children With Cystic Fibrosis
Source: ClinicalTrials.gov · Last updated 2 Apr 2026
Brief summary (registry, in English)
This research aims to evaluate the effects of upper and lower limb exercises on muscle strength and pulmonary function in children diagnosed with CF. While aerobic training is a known component of CF management, resistance training focused on specific limb groups has gained attention for its additional benefits. Upper limb exercises may aid respiratory muscle endurance and thoracic mobility, enhancing pulmonary mechanics. In contrast, lower limb exercises (such as cycling or squats) are associated with improved oxygen consumption (VO₂ peak), enhanced mobility, and greater lower body strength. This randomized clinical trial will be conducted using a non-probability convenience sampling technique. The study will take place at the pediatric cystic fibrosis centers of Gulab Devi Chest Hospital and The Children's Hospital, Lahore. The targeted population includes children aged 6 to 18 years who have been diagnosed with cystic fibrosis and referred to the physiotherapy department. The study duration will be ten months following the approval of the synopsis. Eligible participants will be children aged between 6 and 18 years, clinically diagnosed with cystic fibrosis, currently stable with no history of hospitalization or significant lung infection in the past month. They should be physically able to participate in exercise and capable of following instructions, with informed consent obtained from their parents or guardians. Children will be excluded if they suffer from other severe lung diseases, cardiovascular or orthopedic conditions that restrict exercise, recent surgery or hospitalization within the last month, or if they are unable to understand instructions. Those dependent on oxygen therapy or ventilator support at all times will also be excluded. The primary outcome measures will include lung function assessed by spirometry (FVC, FEV1), sputum production recorded through a sputum diary, and aerobic capacity measured by the Incremental Shuttle Walk Test (ISWT). Muscle strength will be evaluated for both upper and lower limbs, using a handheld dynamometer for the upper limbs and the Sit-to-Stand Test for the lower limb
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 22 (estimated)
- First submitted
- 16 Mar 2026
- Start date
- Dec 2025
- Primary completion date
- Aug 2026
- Lead sponsor
- Riphah International University
- Diseases
- Cystic fibrosis
- NCT number
- NCT07508904
What you commit to
- Study type: Interventional
- Planned participants: 22
- From Dec 2025 to the primary completion date, Aug 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Surgery or hospitalization within last 1 month
Other illness
- Other severe pulmonary diseases
Other
- Cardiovascular or orthopedic limitations
- Inability to follow instructions
- Oxygen-dependent or ventilator-dependent patients
Who the study is looking for
- Children aged 6-18 years
- Diagnosed with cystic fibrosis
- Clinically stable
- Able to perform exercise
- Parental/guardian consent provided
Age in the registry: 6 years to 18 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Gulab Devi Chest Hospital Coordinator of this site? Confirm its status | Lahore | Pakistan | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.